MariMed Year-Over-Year Profits Sink, But Expansion Continues

marimed3
The company recently added additional stores in Massachusetts.

MariMed Inc. (CSE: MRMD) (OTCQX: MRMD) lost $664,000 in the first quarter of 2023, a sharp drop from the $4.2 million profit the company posted in the same period in 2022.

The Massachusetts-based multistate operator posted $34.3 million in revenues for Q1 and had $21.5 million in cash as of March 31. That led CEO Jon Levine to boast of “another solid quarter” in a press release, in which he also highlighted MariMed’s four-year streak of positive operating cash flows.

“MariMed is one of the only companies in the cannabis industry to report positive cash flows and positive EBITDA over this extended period of time,” Levine said.

Chief Financial Officer Susan Villare called the Q1 results “very strong” and said leadership is “maintaining our positive outlook and guidance for 2023.”

“Our balance sheet remains conservatively leveraged and our ability to generate positive cash flows from operations remains a core strength of the company,” Villare said.

This year, MariMed is projecting:

  • Minimum annual revenue of $150 million.
  • Gross margin of “about 48%.”
  • Capital expenditures of $30 million.

Also during the first quarter, MariMed closed a $35 million secured credit facility, with $30 million available immediately and another $5 million available in June, if necessary, all at an interest rate of 5.75% for three years. The funds will be used for capital improvements, acquisitions, and “other corporate expenses.”

In March, the company acquired a Massachusetts competitor, vertically integrated Ermont Inc. in Quincy. The retail portion of Ermont was rebranded to Panacea Wellness Dispensary, which is part of MariMed’s portfolio.

Then in April, MariMed opened its third medical cannabis shop in Massachusetts, another Panacea Wellness Dispensary in Beverly, and got its annual approval from Maryland regulators to continue producing high-dose 40-milligram medical edibles.

Avatar photo

John Schroyer

John Schroyer has been a reporter since 2006, initially with a focus on politics, and covered the 2012 Colorado campaign to legalize marijuana. He has written about the cannabis industry specifically since 2014, after being on hand for the first-ever legal cannabis sales on New Year’s Day that year in Denver. John has covered subsequent marijuana market launches in California and Illinois, has written about every aspect of the marijuana trade, and was part of the team that built the cannabis industry’s first-ever trade show, MJBizCon. He joined Green Market Report in 2022.


One comment

  • FarnazInanlou

    May 8, 2023 at 7:05 pm

    Baffling that you should post such an uninformed piece. Zero research was done.

    Reply

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.

 Sign up


About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


READ MORE



Recent Tweets